CDK6 (Cyclin-dependent kinase 6)

This study provides novel insights into the genetic blueprint of bGBM. Further research with larger cohorts is needed to validate these findings and better understand the molecular features of bGBM.

L6565 exhibited homozygous CDKN2A loss with retained Rb expression, rendering tumour cells sensitive to CDK4/CDK6 inhibition via palbociclib. Tumour heterogeneity was reflected in advanced culture methods producing more variability in treatment response. These results highlight the potential of genome-informed therapies in osteosarcoma and the importance of refining culture techniques to enhance translational research and therapeutic outcomes.

Silencing of SNHG10 decreases cell survival, proliferation, clonogenicity, EMT tumor growth through the EGFR/AKT/ERK/mTOR axis, and restores the expression of miR-150-5p, which eventually downregulates VEGF-A. SNHG10 downregulation enhanced the gemcitabine sensitivity in gemcitabine-resistant PDAC cells.

Top docked complexes, such as CDK1-Michelalbine (Indian) and CDK1-Emodin (Chinese), alongside CDK1-Doxorubicin (conventional), were subjected to Molecular Dynamic Simulation for comparative analysis...This comprehensive in-silico approach uncovers potential novel therapeutic options for targeting CDKs in breast cancer. The online version contains supplementary material available at 10.1007/s40203-026-00613-8.

Integrating subgroup-specific genetic events with clinical features facilitates MB risk stratification, informs context-dependent radiotherapy consideration, and provides actionable candidates for prospective validation.

Curcumol reduced SKP2 expression, weakened the interaction between SKP2 and p27, inhibited degradation of p27, and then induced G1 phase cell-cycle arrest in SK-Hep-1 cells.

The FMF-02 trial is the first randomized phase IIb study directly comparing the novel inhibitor FM against RUX. Its findings are expected to generate pivotal evidence regarding whether FM offers superior or differentiated clinical benefits, thereby informing its potential as a frontline therapy for intermediate- to high-risk MF and guiding the design of future phase III studies.

Additionally, ononin restricted tumor growth, decreased Ki67 and p-AKT expression, and curbed lung metastasis in xenograft mouse models. Ononin inhibits HCC growth and metastasis by downregulating MMP-2 and MMP-9 through inactivating the PI3K/AKT/mTOR signaling.

The HDAC8 PROTAC demonstrated stronger antitumor activity than HDAC8i and pan-HDACi vorinostat...HDAC8 PROTAC selectively suppressed glioblastoma cell growth and viability by arresting the cell cycle and inducing ER stress-mediated apoptosis via the IRE1α/XBP1s-JNK-CHOP pathway. Hence, HDAC8 PROTAC is a potential therapeutic agent for glioblastoma treatment.

Among them, compound 1a displayed the most potent activity against Eca109 cells, with an IC50 value of 6.84 μM, being markedly lower than those of curcumin (29.5 μM) and cisplatin (10.4 μM), indicating superior cytotoxicity. Molecular docking analysis of 1a predicted strong binding to EGFR (-10.9 kcal/mol) and CDK6 (-11.2 kcal/mol), stabilized by hydrogen bonds and hydrophobic interactions. These results validate the novelty of indole modification and correlate in vitro activity with in silico mechanisms.

Compensatory mechanisms under the single treatments might include activation of CDK1/2 and the DNA damage response, as assessed by the activation of phospho-Chk2, since this was perturbed under the combinatorial treatments. Taken together, our work identifies combinatorial treatments that substantially reduce the viability of spheroidal BON-1 cultures and patient-derived primary cultures as potential novel therapies for the treatment of pNETs.

Many of the mutations described implicate driver mutations in advanced-stage MF and have been associated with poor survival. While there is no evidence suggesting a singular mutation for the pathogenesis of LCT, the constellation of mutations may be responsible for histologic progression to LCT.